Matches in Wikidata for { <http://www.wikidata.org/entity/Q96120675> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q96120675 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96120675 description "im Juni 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q96120675 description "scientific article published on 02 June 2020" @default.
- Q96120675 description "wetenschappelijk artikel" @default.
- Q96120675 description "наукова стаття, опублікована 2 червня 2020" @default.
- Q96120675 name "Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?" @default.
- Q96120675 name "Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?" @default.
- Q96120675 type Item @default.
- Q96120675 label "Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?" @default.
- Q96120675 label "Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?" @default.
- Q96120675 prefLabel "Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?" @default.
- Q96120675 prefLabel "Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?" @default.
- Q96120675 P1433 Q96120675-271427D1-8E15-4AE5-8C4A-9E5F12F01013 @default.
- Q96120675 P1476 Q96120675-4C459CFC-B959-45F8-8EE8-5E1BDC03EB44 @default.
- Q96120675 P2093 Q96120675-639517B8-E553-4DAC-AC61-F43A039F5D2A @default.
- Q96120675 P2093 Q96120675-93BE55BE-3828-441A-A0F5-6041524EFD81 @default.
- Q96120675 P2093 Q96120675-ACC333FF-AC4C-4776-BBD3-388720F3C553 @default.
- Q96120675 P275 Q96120675-878F5C39-9C5B-4BEA-9F2E-05C54ACDE0B3 @default.
- Q96120675 P304 Q96120675-98F1DF65-CDDE-4ED7-8115-CD7060EC8172 @default.
- Q96120675 P31 Q96120675-4EA9B137-0400-48D3-936A-7BD56F8BA02D @default.
- Q96120675 P356 Q96120675-F17869CB-4F5B-41B5-A8D2-E5392E89E1A8 @default.
- Q96120675 P50 Q96120675-CF9A067E-6F67-4753-A4FE-811EC54CEF44 @default.
- Q96120675 P50 Q96120675-E257C409-A85F-4F7E-BAAC-4ADC91096F40 @default.
- Q96120675 P577 Q96120675-9E0C6E58-2BA3-4D6C-A787-2B6CFF07A03C @default.
- Q96120675 P6216 Q96120675-4F71F381-8A5D-44A9-A175-FF60E161EA1A @default.
- Q96120675 P698 Q96120675-0B81795C-72CE-4766-90CC-CC0EE9138E66 @default.
- Q96120675 P921 Q96120675-90FF2E37-197C-40EB-BBFA-E3A75F8F6D94 @default.
- Q96120675 P921 Q96120675-CBAB972D-13D2-4F67-9248-BDDF79E80051 @default.
- Q96120675 P356 1932296820932155 @default.
- Q96120675 P698 32486846 @default.
- Q96120675 P1433 Q15755249 @default.
- Q96120675 P1476 "Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?" @default.
- Q96120675 P2093 "Kalliopi Kotsa" @default.
- Q96120675 P2093 "Pantelis Zebekakis" @default.
- Q96120675 P2093 "Ramzi A Ajjan" @default.
- Q96120675 P275 Q20007257 @default.
- Q96120675 P304 "1932296820932155" @default.
- Q96120675 P31 Q13442814 @default.
- Q96120675 P356 "10.1177/1932296820932155" @default.
- Q96120675 P50 Q122048054 @default.
- Q96120675 P50 Q51935840 @default.
- Q96120675 P577 "2020-06-02T00:00:00Z" @default.
- Q96120675 P6216 Q50423863 @default.
- Q96120675 P698 "32486846" @default.
- Q96120675 P921 Q81068910 @default.
- Q96120675 P921 Q84263196 @default.